US FDA clarifies what constitutes 'minor' change to biologic production process

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmaceutical drug, Pharmacology, Food and drug administration

The US FDA has sought to clarify when biologics firms should inform it about minor changes to manufacturing processes in draft guidance this week.

The US Food and Drug Administration (FDA) draft guidance​  sets out what changes to manufacturing processes and facilities, production equipment and storage systems it considers to be “minor.”

The FDA said: “The number of CMC manufacturing supplements for BLAs has continued to increase over the last several years.

In connection with FDA’s Pharmaceutical Product Quality Initiative and our risk-based approach to CMC review, we have evaluated the types of changes that have been submitted in postapproval manufacturing supplements and determined that certain changes being reported generally present minimal risk to the quality of the product​.”


Under current FDA guidelines​ biologics license application holders are required to assess the impact of and report all postapproval changes. However, the way they must report them varies based on the scale of the change.

Drug firms that plan to make “major” changes to production processes must seek FDA approval before shipping any products made through the new process.

Moderate changes – those deemed to have moderate potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug – must be logged with the agency 30 days before product is distributed.

Minor changes to production processes, in contrast, need only be recorded in an annual report submitted to the FDA.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more